Emerging therapeutics in Huntington's disease
INTRODUCTION: Huntington's disease is a neurodegenerative disease that is characterized by motor dysfunction, behavioral/psychiatric symptoms, and cognitive impairment. Because of the lack of availability of curative or disease modifying treatments, much of clinical practice in HD care to date has focused on symptomatic treatment. Recent work has created optimism surrounding possible emerging disease modifying therapeutics. HD is a developing therapeutic field with diverse and promising emerging therapies.
AREAS COVERED: A PubMed literature review was completed to discover pertinent reviews and analyses. ClinicalTrials.gov was referenced to find updated information about ongoing and planned trials. Lastly, because of the rapidly evolving nature of HD treatments, drug manufacturer websites and press releases were reviewed to provide current information surrounding recently reported trial results.
EXPERT OPINION: Recent setbacks involving antisense oligonucleotide research should not diminish enthusiasm and hope for the many other novel therapies currently being pursued. We remain optimistic about the many promising emerging therapies for HD, and we expect that growing knowledge about the pathophysiology of the underlying disease and constant advances in biotechnology will lead to therapies that have a meaningful impact in the lives of patients, their families, and those who care for them.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Expert opinion on emerging drugs - 26(2021), 3 vom: 01. Sept., Seite 295-302 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wiggins, Robert [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ASO |
|---|
| Anmerkungen: |
Date Completed 26.01.2022 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14728214.2021.1962285 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328645079 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328645079 | ||
| 003 | DE-627 | ||
| 005 | 20231225203356.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14728214.2021.1962285 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1095.xml |
| 035 | |a (DE-627)NLM328645079 | ||
| 035 | |a (NLM)34319843 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wiggins, Robert |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging therapeutics in Huntington's disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Huntington's disease is a neurodegenerative disease that is characterized by motor dysfunction, behavioral/psychiatric symptoms, and cognitive impairment. Because of the lack of availability of curative or disease modifying treatments, much of clinical practice in HD care to date has focused on symptomatic treatment. Recent work has created optimism surrounding possible emerging disease modifying therapeutics. HD is a developing therapeutic field with diverse and promising emerging therapies | ||
| 520 | |a AREAS COVERED: A PubMed literature review was completed to discover pertinent reviews and analyses. ClinicalTrials.gov was referenced to find updated information about ongoing and planned trials. Lastly, because of the rapidly evolving nature of HD treatments, drug manufacturer websites and press releases were reviewed to provide current information surrounding recently reported trial results | ||
| 520 | |a EXPERT OPINION: Recent setbacks involving antisense oligonucleotide research should not diminish enthusiasm and hope for the many other novel therapies currently being pursued. We remain optimistic about the many promising emerging therapies for HD, and we expect that growing knowledge about the pathophysiology of the underlying disease and constant advances in biotechnology will lead to therapies that have a meaningful impact in the lives of patients, their families, and those who care for them | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ASO | |
| 650 | 4 | |a HD | |
| 650 | 4 | |a HTT | |
| 650 | 4 | |a Huntington’s disease | |
| 650 | 4 | |a antisense oligonucleotides | |
| 650 | 4 | |a chorea | |
| 650 | 4 | |a huntingtin | |
| 650 | 4 | |a huntington disease | |
| 650 | 7 | |a Oligonucleotides, Antisense |2 NLM | |
| 700 | 1 | |a Feigin, Andrew |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on emerging drugs |d 2001 |g 26(2021), 3 vom: 01. Sept., Seite 295-302 |w (DE-627)NLM143290835 |x 1744-7623 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2021 |g number:3 |g day:01 |g month:09 |g pages:295-302 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14728214.2021.1962285 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2021 |e 3 |b 01 |c 09 |h 295-302 | ||